- Home
- GENK vs SYBX Comparison
GENK vs SYBX Comparison
Compare GENK & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | SYBX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 15.2M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | SYBX |
|---|---|---|
| Price | $2.25 | $1.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 52.5K | ★ 68.3K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,449,000.00 | N/A |
| Revenue This Year | $11.49 | N/A |
| Revenue Next Year | $13.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $2.20 | $0.90 |
| 52 Week High | $8.45 | $1.96 |
Technical Indicators
Market Signals| Indicator | GENK | SYBX |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 25.48 |
| Support Level | $2.20 | $1.01 |
| Resistance Level | $2.41 | $1.20 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 8.97 | 9.72 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.